An official website of the United States government
Home
SEER Inquiry System - Report
Produced: 10/29/2026 4:51 PM
Question 20260022
Inquiry Details
References:
#1: SEER Manual, 246-248. 2026
#2: SEER*Rx
Question:
First Course Treatment/Other Therapy--Glioblastoma: Is Dendritic Cell/Tumor Cell Electrofusion Cancer Vaccine, coded to Immunotherapy as stated in SEER*Rx? A patient, diagnosed with Glioblastoma (GBM) IDH-wildtype (CNS WHO grade 4), in addition to radiation and chemotherapy, was enrolled on Diakonos/DOC-DBM study, randomized to the vaccine arm. It seems this study evaluates dubodencel, a novel dendritic cell vaccine treating GBM.
Discussion:
Answer:
Code dubodencel to Other Therapy, code 2 (other-experimental). Dubodencel is not technically Dendritic Cell/Tumor Cell Electrofusion Cancer Vaccine, though close. However, both are in early stages of clinical development. We updated the coding instructions for Dendritic Cell/Tumor Cell Electrofusion Cancer Vaccine in SEER*Rx.
